Dermaliq Therapeutics Inc. – Trademark Portfolio
Entity Type: 03
Dermaliq Therapeutics Inc. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include HYLIQ and IQDINE.
1201 North Market Street, Suite 111
Wilmington DE 19801
Showing of trademarks Trademarks
Trademark Classifications
Dermaliq Therapeutics Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Dermaliq Therapeutics Inc. have?
Dermaliq Therapeutics Inc. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Dermaliq Therapeutics Inc. file in?
Dermaliq Therapeutics Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Dermaliq Therapeutics Inc.'s most well-known trademarks?
Dermaliq Therapeutics Inc.'s registered trademark portfolio includes well-known marks such as HYLIQ and IQDINE. These are among 2 currently registered trademarks in the portfolio.
What is Dermaliq Therapeutics Inc.'s trademark registration success rate?
Dermaliq Therapeutics Inc. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.